

業績目録 (平成30年)

教室・部門名 分子診断・治療医学

(A-a) 英文著書

(A-b) 和文著書

(B-a) 英文総説

- 1 Taniwaki M, Yoshida M, Matsumoto Y, Shimura K, Kuroda J, Kaneko H. Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling. *Mediterr J Hematol Infect Dis.* 2018 Feb 15;10(1):e2018014. (IF= 1.586)

(B-b) 和文総説

- 1 谷脇 雅史. 血液腫瘍の分子細胞遺伝学：基礎と臨床. 日本染色体遺伝子検査学会雑誌 36 : 9-25, 2018.

(C-a) 英文原著

- 1 Watanabe T, Tobinai K, Wakabayashi M, Morishima Y, Kobayashi H, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Yoshino T, Nawano S, Terauchi T, Hotta T, Nagai H, Tsukasaki K; JCOG0203 Collaborators. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. *Lancet Haematol.* 2018 Nov;5(11):e520-e531. (IF= 10.698)
- 2 Mizuno S, Hanamura I, Ota A, Karnan S, Kanasugi J, Nakamura A, Takasugi S, Uchino K, Horio T, Goto M, Murakami S, Gotou M, Yamamoto H, Watarai M, Shikami M, Hosokawa Y, Miwa H, Taniwaki M, Ueda R, Nitta M, Takami A. Establishment and characterization of a novel vincristine-resistant diffuse large B-cell lymphoma cell line containing the 8q24 homogeneously staining region. *FEBS Open Bio.* 2018 Nov 20;8(12):1977-1991. (IF= 1.782)

- 3 Maruyama D, Tobinai K, Chou T, Taniwaki M, Shumiya Y, Iida S. Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial. *Cancer Sci.* 2018 Oct;109(10):3245–3252. (IF= 4.751)
- 4 Ohmachi K, Tobinai K, Kinoshita T, Ishikawa T, Hatake K, Ichikawa S, Ohmine K, Kamitsuji Y, Choi I, Chou T, Tsukasaki K, Kumagai K, Taniwaki M, Uchida T, Kikukawa Y, Kubo K, Mihara K, Tsukamoto N, Izutsu K, Yoshida I, Ishida F, Usui N, Iida S, Murayama T, Ueda E, Kuriki H, Ando K. Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial. *Int J Hematol.* 108(5):499–509, 2018. (IF=2.251)
- 5 Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, Uike N, Kurosawa M, Gomyo H, Taniwaki M, Nosaka K, Tsukamoto N, Shimoyama T, Fukuhara N, Yakushijin Y, Ohnishi K, Miyazaki K, Sawada K, Takayama N, Hanamura I, Nagai H, Kobayashi H, Usuki K, Kobayashi N, Ohyashiki K, Utsumi T, Kumagai K, Maruyama D, Ohmachi K, Matsuno Y, Nakamura S, Hotta T, Tsukasaki K; Japan Clinical Oncology Group- Lymphoma Study Group (JCOG-LSG). R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY. *Cancer Sci.* 109(9):2830–2840, 2018. (IF=4.751)
- 6 Kaneko H, Taniwaki M, Matsumoto Y, Yoshida M, Shimura K, Fujino T, Uchiyama H, Kuroda J. An adult-onset case of chronic active Epstein-Barr virus infection with fulminant clinical course. *J Infect Chemother.* 24(6):479–482, 2018. (IF= 1.669)
- 7 Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators (including Taniwaki M). Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus

rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. *Lancet Oncol.* 2018;19(11):1449-1458. (IF=35.386).

- 8 Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C, Ptáčník V, Rosta A, Fingerle-Rowson GR, Zhu J, Nielsen T, Sahin D, Hiddemann W, Marcus RE, Davies A; PET investigators from the GALLIUM study (including Taniwaki M). Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. *Lancet Oncol.* 2018;19(11):1530-1542. (IF=35.386)
- 9 Kobayashi Y, Munakata W, Ogura M, Uchida T, Taniwaki M, Kobayashi T, Shimada F, Yonemura M, Matsuoka F, Tajima T, Yakushijin K, Minami H. Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. *Int J Hematol.* 2018;107(1):83-91. (IF=2.251)
- 10 Ri M, Suzuki K, Iida S, Hatake K, Chou T, Taniwaki M, Watanabe N, Tsukamoto T. A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma. *Intern Med.* 2018;57(7):939-946. (IF=0.956)

(C-b) 和文原著

(D) 学会発表

(E) 研究助成 (競争的研究助成金)

総額 270 万円

公的助成

代表（総額）・小計 220 万円

- 1 文部科学省科学研究費助成事業 基盤研究 (C) 平成 28～30 年度
難治性リンパ腫における MYC, PVT1 再構成・発現の解析と臨床応用
助成金額 80 万円
- 2 文部科学省科学研究費助成事業 基盤研究 (C) 平成 30～32 年度
ファミリー遺伝子に内在する新たな造白血病活性抑制機構の解明
助成金額 140 万円

財団等からの助成

代表（総額）・小計 50 万円

- 1 一般社団法人日本血液学会 研究助成 平成 30 年度
血液腫瘍における染色体 8q24 転座と長鎖非コード RNA PVT1 の解析：難治
性の分子機構解明と臨床応用
助成金額 50 万円